Washington Trust Advisors’s Genmab GMAB Stock Holding History

Washington Trust Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.38K	Hold	196	–	–	﹤0.01%	563
2026 Q1	$5.26K	Sell	196 -45	-19%	-$1.35K	﹤0.01%	531
2025 Q4	$7.42K	Hold	241	–	–	﹤0.01%	522
2025 Q3	$7.39K	Buy	241 +45	+23%	+$1.1K	﹤0.01%	570
2025 Q2	$4.05K	Hold	196	–	–	﹤0.01%	585
2025 Q1	$3.84K	Buy	196 +176	+880%	+$3.69K	﹤0.01%	573
2024 Q4	$417	Buy	+20	New	+$439	﹤0.01%	642
2024 Q3	–	Sell	-167	Closed	-$4.2K	–	674
2024 Q2	$4.2K	Hold	167	–	–	﹤0.01%	583
2024 Q1	$5K	Hold	167	–	–	﹤0.01%	572
2023 Q4	$5.32K	Hold	167	–	–	﹤0.01%	565
2023 Q3	$5.89K	Buy	+167	New	+$6.36K	﹤0.01%	526

Other funds holding GMAB

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Washington Trust Advisors's GMAB Position: Q2 2026 in Review

Washington Trust Advisors held its Genmab (GMAB) position steady in Q2 2026 at 196 shares worth $5.38K. The position accounts for ﹤0.01% of the portfolio, ranked #563.

Washington Trust Advisors first reported a position in GMAB in Q3 2023 and has held it in 11 quarters since. The position peaked at $7.42K in Q4 2025. 290 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

Washington Trust Advisors held 196 shares of Genmab worth $5.38K as of Q2 2026.
Washington Trust Advisors left its Genmab share count unchanged in Q2 2026.
Genmab made up ﹤0.01% of Washington Trust Advisors's portfolio in Q2 2026, its #563 holding.
Washington Trust Advisors first reported a position in Genmab in Q3 2023 and has held it in 11 quarters since.
Washington Trust Advisors's Genmab position peaked at $7.42K in Q4 2025.
290 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Washington Trust Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.